SBI Biotech, a company specializing in targeting autoimmune diseases operating dendritic cell platform-based for immune modulation drugs, is working on developing new medicines with the vision of contributing to society through creating treatment methods for intractable diseases and innovative new drugs.
The immune modulation drug is one of the candidates to treat cancer by activating immune response and autoimmune diseases by suppressing overreaction. The drugs are researched and developed by the SBI Biotech and act on plasmacytoid dendritic cells (pDCs), which control the body's immune response.
We have been licensing out multiple drug candidates to pharmaceutical companies to approve and sell new drugs after verifying their efficacy and safety through clinical trials.
